Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor–Positive/HER2–Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520)

Key Points

• The research aimed to evaluate the clinical impact of Oncotype DX on treatment decisions in early breast cancer.
• Analysis of a large Brazilian cohort from GBECAM 0520.
• Evaluation of Oncotype DX for guiding adjuvant chemotherapy (ACT) decisions.
• Assessment of surrogate markers such as Ki-67, PR expression, and histologic grade.
• Oncotype DX reduced rates of overtreatment and undertreatment.
• Surrogate markers provided practical tools for risk-adapted clinical decisions.

Abstract